Financial health
- The company holds more cash ($183M) than total debt ($55M).
- Operating income covered interest expense -120.0× in the latest year.
NMRA Financials Neumora Therapeutics, Inc.
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Net income
ROEROA
Equity
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | $237M | — | — | 228.1% | 124.0% | — | $55M | $183M |
| 2024 | — | $244M | — | — | 84.9% | 76.9% | — | $0 | $142M |
| 2023 | — | -$236M | — | — | -50.3% | -47.5% | -$163M | — | $374M |
| 2022 | — | -$131M | — | — | 29.3% | -30.7% | -$115M | — | $241M |
Net income
ROEROA
Equity
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$43M | — | — | -96.8% | -34.4% | — | $53M | $117M |
| Mar '26 | — | -$53M | — | — | -75.6% | -34.7% | — | $53M | $147M |
| Dec '25 | — | -$59M | — | — | -57.2% | -31.1% | — | $55M | $183M |
| Sep '25 | — | -$57M | — | — | -42.9% | -31.9% | — | $20M | $129M |
| Jun '25 | — | -$53M | — | — | -28.8% | -23.6% | — | $19M | $125M |
| Mar '25 | — | -$68M | — | — | -29.8% | -26.5% | — | — | $127M |
| Dec '24 | — | -$59M | — | — | -20.5% | -18.6% | — | $0 | $142M |
| Sep '24 | — | -$73M | — | — | -22.6% | -20.6% | — | — | $276M |
| Jun '24 | — | -$59M | — | — | -15.4% | -14.5% | — | — | $151M |
| Mar '24 | — | -$54M | — | — | -12.7% | -11.9% | — | — | $183M |
| Dec '23 | — | -$109M | — | — | -23.2% | -21.9% | -$51M | — | $374M |
| Sep '23 | — | -$53M | — | — | -10.3% | -9.7% | -$48M | — | $412M |
| Jun '23 | — | -$39M | — | — | 7.5% | — | -$31M | — | $204M |
| Mar '23 | — | -$36M | — | — | 7.5% | — | -$33M | — | $211M |
| Dec '22 | — | -$28M | — | — | 6.3% | -6.6% | -$30M | — | $241M |
| Sep '22 | — | -$29M | — | — | 7.0% | — | — | — | $253M |
| Jun '22 | — | -$30M | — | — | 7.7% | — | — | — | — |
| Mar '22 | — | -$43M | — | — | 11.8% | — | — | — | — |
Valuation over time
How the market has priced NMRA against its own fundamentals since 2023-09 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 1.6× (Dec '24) to 1.1× (Sep '26).
P/E
Frequently asked questions
Is NMRA growing its revenue and profit?
See the revenue and net-income charts above for Neumora Therapeutics, Inc.'s multi-year trend.
How much debt does NMRA have?
As of FY2025, Neumora Therapeutics, Inc. reported $55M of total debt against $183M of cash; operating income covered interest expense -120.0×.
What is NMRA's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is NMRA's P/E ratio?
As of Sep '26, Neumora Therapeutics, Inc. traded at a price-to-earnings ratio of about 1.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.